Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by retiredcopon Oct 04, 2022 10:18am
149 Views
Post# 35003833

New CEO

New CEO I few have asked why I am so impressed with the new CEO. And as I mentioned this is my opinion of what I think, There are no quotes ( you can contact her yourself if you need one )  The first thing ..is that she does not have to resort to outlining her CV to get the attention of the her audience. I think she  functions in the updated world and sees the great benefit of social media and she has ALOT of contacts/followers. I think I would explain her best quality as ...her reputation proceeds her. This is the type of credibility we have been lacking fowever. To me this translates into new interest in the company and leaves us with many different types of financial support for the company .. not just private placements like we are used to. Taking advantage of Neils abilities and his accomplishments, the extrodinary science at PMN and the identified needs of the gobal health community ... and getting this out to the world seems to be a theme I sensed. We need to constantly promote our strong points to the investment, science and health segments of society. 

We will get to know her much better in the next while, so please keep in mind that I came to my conclusions with her only being on the job for 4 days and a first impression. At this point she seems to be open to inquires directed at her, so take advantage of that.       
<< Previous
Bullboard Posts
Next >>